DE4310643A1
(de)
*
|
1993-04-01 |
1994-10-06 |
Merck Patent Gmbh |
Cyclische Adhäsionsinhibitoren
|
US5753230A
(en)
*
|
1994-03-18 |
1998-05-19 |
The Scripps Research Institute |
Methods and compositions useful for inhibition of angiogenesis
|
US5945403A
(en)
*
|
1997-05-30 |
1999-08-31 |
The Children's Medical Center Corporation |
Angiostatin fragments and method of use
|
US5837682A
(en)
|
1996-03-08 |
1998-11-17 |
The Children's Medical Center Corporation |
Angiostatin fragments and method of use
|
US6949511B1
(en)
|
1994-04-26 |
2005-09-27 |
The Children's Medical Center Corporation |
Methods of inhibiting angiogenesis via increasing in vivo concentrations of kringle region fragments of plasminogen
|
US6660842B1
(en)
|
1994-04-28 |
2003-12-09 |
Tripep Ab |
Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
|
DK0719859T3
(da)
*
|
1994-12-20 |
2003-10-20 |
Merck Patent Gmbh |
Anti-alfa V-integrin monoklonalt antistof
|
US6358735B1
(en)
|
1995-06-30 |
2002-03-19 |
University Of Kansas Medical Center |
Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
|
US6440729B1
(en)
*
|
1995-06-30 |
2002-08-27 |
University Of Kansas Medical Center |
Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
|
CA2754102C
(en)
*
|
1995-08-14 |
2012-12-18 |
The Scripps Research Institute |
Monoclonal antibodies and compositions comprising such useful for inhibition of .alpha.v.beta.5 mediated angiogenesis
|
US6100423A
(en)
*
|
1995-08-30 |
2000-08-08 |
G. D. Searle & Co. |
Amino benzenepropanoic acid compounds and derivatives thereof
|
ES2161373T3
(es)
|
1995-08-30 |
2001-12-01 |
Searle & Co |
Derivados de meta-guanidina, urea, tiourea o acido azaciclico-aminobenzoico como antagonistas de integrinas.
|
US6346510B1
(en)
|
1995-10-23 |
2002-02-12 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic endostatin compositions
|
US5854205A
(en)
*
|
1995-10-23 |
1998-12-29 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic compositions and methods
|
JP3840262B2
(ja)
|
1995-10-23 |
2006-11-01 |
ザ チルドレンズ メディカル センター コーポレイション |
治療用の抗血管新生組成物および方法
|
US5854221A
(en)
*
|
1996-12-12 |
1998-12-29 |
The Children's Medical Center Corporation |
Endothelial cell proliferation inhibitor and method of use
|
DE69727582T2
(de)
*
|
1996-08-15 |
2004-12-23 |
Novartis Ag |
Test zur quantifizierung von arthritiszustanden
|
GB9708265D0
(en)
*
|
1997-04-24 |
1997-06-18 |
Nycomed Imaging As |
Contrast agents
|
DE69739295D1
(de)
*
|
1996-12-09 |
2009-04-23 |
Merck Patent Gmbh |
Löslicher, rekombinanter alphaV beta3 Adhäsionsrezeptor
|
US6590079B2
(en)
|
1997-01-30 |
2003-07-08 |
Ixsys, Incorporated |
Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
|
US6596850B1
(en)
|
1998-01-30 |
2003-07-22 |
Ixsys, Incorporated |
Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
|
EP0968290B1
(en)
*
|
1997-03-12 |
2004-12-15 |
SmithKline Beecham Corporation |
Anti-alphavbeta3 humanized monoclonal antibodies
|
US7112338B2
(en)
|
1997-03-12 |
2006-09-26 |
The Regents Of The University Of California |
Cationic liposome delivery of taxanes to angiogenic blood vessels
|
US5837283A
(en)
|
1997-03-12 |
1998-11-17 |
The Regents Of The University Of California |
Cationic lipid compositions targeting angiogenic endothelial cells
|
US5994388A
(en)
*
|
1997-03-18 |
1999-11-30 |
The Children's Medical Center Corporation |
Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
|
WO1998041158A1
(en)
*
|
1997-03-19 |
1998-09-24 |
Lucid Technologies, Inc. |
Cellular surgery utilizing confocal microscopy
|
JP2001521520A
(ja)
*
|
1997-04-11 |
2001-11-06 |
ジー.ディー.サール アンド カンパニー |
抗α▲下v▼β▲下3▼インテグリン抗体アンタゴニスト
|
AU6954498A
(en)
*
|
1997-04-11 |
1998-11-11 |
G.D. Searle & Co. |
Methods for using antagonistic anti-avb3 integrin antibodies
|
US6596276B1
(en)
*
|
1997-09-30 |
2003-07-22 |
Beth Israel Deaconess Medical Center |
Method for inhibiting tumor angiogenesis in a living subject
|
US6172256B1
(en)
*
|
1998-03-04 |
2001-01-09 |
G.D. Searle & Co. |
Chiral-β-amino acid compounds and derivatives thereof
|
US6372719B1
(en)
*
|
1998-03-04 |
2002-04-16 |
Jay Cunningham |
ανβ3 integrin antagonists in combination with chemotherapeutic agents
|
US6537520B1
(en)
|
1998-03-31 |
2003-03-25 |
Bristol-Myers Squibb Pharma Company |
Pharmaceuticals for the imaging of angiogenic disorders
|
IL138093A0
(en)
|
1998-03-31 |
2001-10-31 |
Du Pont Pharm Co |
Pharmaceuticals for the imaging of angiogenic disorders
|
US6548663B1
(en)
|
1998-03-31 |
2003-04-15 |
Bristol-Myers Squibb Pharma Company |
Benzodiazepine vitronectin receptor antagonist pharmaceuticals
|
US6524553B2
(en)
|
1998-03-31 |
2003-02-25 |
Bristol-Myers Squibb Pharma Company |
Quinolone vitronectin receptor antagonist pharmaceuticals
|
US6852318B1
(en)
*
|
1998-05-08 |
2005-02-08 |
The Regents Of The University Of California |
Methods for detecting and inhibiting angiogenesis
|
US6759047B1
(en)
*
|
1998-06-17 |
2004-07-06 |
Beth Israel Deaconess Hospital Corp. |
Anti-angiogenic proteins and methods of use thereof
|
US6962974B1
(en)
|
1998-06-17 |
2005-11-08 |
Beth Israel Deaconess Medical Center |
Anti-angiogenic proteins and fragments and methods of use thereof
|
US7387779B2
(en)
|
1998-06-17 |
2008-06-17 |
Beth Israel Deaconess Medical Center |
Anti-angiogenic proteins and fragments and methods of use thereof
|
AU771224B2
(en)
|
1998-07-13 |
2004-03-18 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using antibodies to aminophospholipids
|
RU2167425C2
(ru)
*
|
1998-07-17 |
2001-05-20 |
Малышев Игорь Юрьевич |
Способ определения белков
|
US6164281A
(en)
*
|
1998-07-20 |
2000-12-26 |
Zhao; Iris Ginron |
Method of making and/or treating diseases characterized by neovascularization
|
WO2000009143A1
(en)
*
|
1998-08-13 |
2000-02-24 |
G.D. Searle & Co. |
Multivalent avb3 and metastasis-associated receptor ligands
|
US6979697B1
(en)
*
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
US6703050B1
(en)
*
|
1998-09-04 |
2004-03-09 |
The Regents Of The University Of Michigan |
Methods and compositions for the prevention or treatment of cancer
|
US6537554B1
(en)
|
1998-09-10 |
2003-03-25 |
Curagen Corporation |
Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
|
US7176289B1
(en)
|
1998-09-11 |
2007-02-13 |
Vanderbilt University |
Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
|
US6248327B1
(en)
|
1998-09-11 |
2001-06-19 |
Vanderbilt University |
Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
|
US6235877B1
(en)
|
1999-08-04 |
2001-05-22 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
|
US20030202977A1
(en)
*
|
1998-11-16 |
2003-10-30 |
New York University |
Treatment of osteoarthritis
|
JP2002530350A
(ja)
*
|
1998-11-20 |
2002-09-17 |
ジェネンテック・インコーポレーテッド |
血管障害を処置するためのEphレセプターのアンタゴニストおよびアゴニストについての使用
|
US6339062B1
(en)
*
|
1998-11-23 |
2002-01-15 |
Inkine Pharmaceutical Company, Inc. |
Retroinverso polypeptides that mimic or inhibit thrombospondin activity
|
US6160099A
(en)
*
|
1998-11-24 |
2000-12-12 |
Jonak; Zdenka Ludmila |
Anti-human αv β3 and αv β5 antibodies
|
CA2727746A1
(en)
|
1998-12-18 |
2000-06-22 |
Bristol-Myers Squibb Pharma Company |
Quinolone vitronectin receptor antagonist pharmaceuticals
|
EP1140864A2
(en)
|
1998-12-18 |
2001-10-10 |
Du Pont Pharmaceuticals Company |
Vitronectin receptor antagonist pharmaceuticals
|
US6569402B1
(en)
*
|
1998-12-18 |
2003-05-27 |
Bristol-Myers Squibb Pharma Company |
Vitronectin receptor antagonist pharmaceuticals
|
US6794518B1
(en)
|
1998-12-18 |
2004-09-21 |
Bristol-Myers Squibb Pharma Company |
Vitronectin receptor antagonist pharmaceuticals
|
US6511649B1
(en)
*
|
1998-12-18 |
2003-01-28 |
Thomas D. Harris |
Vitronectin receptor antagonist pharmaceuticals
|
JP2002533416A
(ja)
*
|
1998-12-23 |
2002-10-08 |
ジー.ディー.サール & カンパニー |
新形成の治療における組み合わせ治療としてのシクロオキシゲナーゼ−2インヒビターおよび一つまたはそれ以上の抗腫瘍薬の使用方法
|
US20050281821A1
(en)
*
|
1999-01-06 |
2005-12-22 |
Flavia Pernasetti |
Method and composition for angiogenesis inhibition
|
US6521593B1
(en)
*
|
1999-02-01 |
2003-02-18 |
Childrens Hospital Los Angeles |
Methods for inhibiting brain tumor growth
|
DK1156823T3
(da)
*
|
1999-02-12 |
2009-01-19 |
Scripps Research Inst |
Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
|
AU4187200A
(en)
*
|
1999-04-01 |
2000-10-23 |
Biostratum, Inc. |
The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
|
WO2000067771A1
(en)
*
|
1999-05-06 |
2000-11-16 |
The Burnham Institute |
Antiangiogenic endostatin peptides, endostatin variants and methods of use
|
US6890904B1
(en)
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
US6531580B1
(en)
|
1999-06-24 |
2003-03-11 |
Ixsys, Inc. |
Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
|
US6685914B1
(en)
|
1999-09-13 |
2004-02-03 |
Bristol-Myers Squibb Pharma Company |
Macrocyclic chelants for metallopharmaceuticals
|
US20080038274A1
(en)
|
1999-09-23 |
2008-02-14 |
Foster Keith A |
Inhibition of secretion from non-neuronal cells
|
MXPA02003079A
(es)
*
|
1999-09-23 |
2004-04-21 |
Scripps Research Inst |
Metodo y composiciones para inhibir la formacion de adhesion.
|
DE60035057T2
(de)
*
|
1999-10-04 |
2008-01-31 |
Novartis Vaccines and Diagnostics, Inc., Emeryville |
CD40 Antagonist zur Behandlung von Psoriasis
|
EP1250155B1
(en)
|
1999-12-22 |
2008-04-16 |
The Scripps Research Institute |
Angiogenesis and vascular permeability modulators and inhibitors
|
US7740841B1
(en)
*
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
DE60141889D1
(de)
*
|
2000-02-03 |
2010-06-02 |
Eisai R&D Man Co Ltd |
Inhibitoren der integrinexpression
|
US7361643B2
(en)
|
2000-02-09 |
2008-04-22 |
University Of Puerto Rico |
Methods for inhibiting angiogenesis
|
AU2001236909A1
(en)
*
|
2000-02-11 |
2001-08-20 |
Duke University |
Method of treating disorders of the eye
|
US6573096B1
(en)
*
|
2000-04-01 |
2003-06-03 |
The Research Foundation At State University Of New York |
Compositions and methods for inhibition of cancer invasion and angiogenesis
|
US6835806B2
(en)
|
2000-04-03 |
2004-12-28 |
Phoenix Pharmaceuticals, Inc. |
Cell growth regulation system
|
JP5043271B2
(ja)
|
2000-04-12 |
2012-10-10 |
ジーイー・ヘルスケア・アクスイェ・セルスカプ |
ペプチドベースの化合物
|
US10293056B1
(en)
*
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
US7163681B2
(en)
*
|
2000-08-07 |
2007-01-16 |
Centocor, Inc. |
Anti-integrin antibodies, compositions, methods and uses
|
US7288390B2
(en)
*
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US20030104573A1
(en)
*
|
2000-09-11 |
2003-06-05 |
Shimkets Richard A. |
Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
|
NO20004795D0
(no)
|
2000-09-26 |
2000-09-26 |
Nycomed Imaging As |
Peptidbaserte forbindelser
|
JP2005508831A
(ja)
*
|
2000-10-02 |
2005-04-07 |
ザ スクリプス リサーチ インスティテュート |
血管新生促進のための方法および組成物
|
US6632835B2
(en)
|
2001-02-22 |
2003-10-14 |
Nanodesign Inc. |
Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
|
DE10109136A1
(de)
*
|
2001-02-26 |
2002-09-12 |
Cytotools Gmbh |
Mittel, die die Apoptose bei an der Wundheilung beteiligten Zellen inhibieren
|
CN1507354A
(zh)
*
|
2001-03-02 |
2004-06-23 |
ͨ��ҽ�ƹ�˾ |
通过给予整合蛋白αvβ3拮抗剂并与其它预防或治疗药剂配合来预防或者治疗炎性疾病或自身免疫疾病的方法
|
KR100861466B1
(ko)
|
2001-04-24 |
2008-10-02 |
메르크 파텐트 게엠베하 |
항혈관형성제 및 TNFα를 이용한 병용 요법
|
SE0101854L
(sv)
*
|
2001-05-28 |
2002-11-29 |
Bioneris Ab |
Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
|
US7829087B2
(en)
*
|
2001-07-09 |
2010-11-09 |
Elan Pharmaceuticals, Inc. |
Methods of treating cognitive impairment
|
CA2453403C
(en)
*
|
2001-07-09 |
2013-10-08 |
Elan Pharmaceuticals, Inc. |
Methods of inhibiting amyloid toxicity
|
CA2452923C
(en)
|
2001-07-10 |
2012-02-07 |
Amersham Health As |
Peptide-based compounds for targeting integrin receptors
|
US7122517B2
(en)
*
|
2001-07-27 |
2006-10-17 |
Kansas University Medical Center |
Crystallized structure of type IV collagen NC1 domain hexamer
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
WO2003020280A2
(en)
*
|
2001-09-05 |
2003-03-13 |
Minerva Biotechnologies Corporation |
Compositions and use thereof in the treatment of cancer
|
WO2003059251A2
(en)
|
2001-10-22 |
2003-07-24 |
The Scripps Research Institute |
Antibody targeting compounds
|
US20050085415A1
(en)
*
|
2002-02-14 |
2005-04-21 |
Matthias Wiesner |
Methods and compositions for the treatment of eye diseases
|
WO2003068258A1
(en)
*
|
2002-02-15 |
2003-08-21 |
Richard Brunner |
7s immunoglobulin for treatment of choroidal neovascularisation_
|
WO2003075957A1
(en)
*
|
2002-03-04 |
2003-09-18 |
Medimmune, Inc. |
The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
|
AU2003213682C1
(en)
*
|
2002-03-04 |
2008-06-12 |
Medimmune, Inc. |
Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
|
US7371383B2
(en)
*
|
2002-04-12 |
2008-05-13 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
EP2269656B1
(en)
|
2002-07-15 |
2014-08-20 |
Board Of Regents, The University Of Texas |
Selected antibodies binding to aminophospholipids and their use in treatment, such as cancer
|
GB0217018D0
(en)
*
|
2002-07-23 |
2002-08-28 |
Bioacta Ltd |
Peptide 1
|
CN1688303A
(zh)
*
|
2002-07-23 |
2005-10-26 |
密歇根大学董事会 |
用于抗血管发生疗法的四硫代钼酸四丙铵及相关化合物
|
EP1578254B1
(en)
*
|
2002-11-19 |
2013-03-06 |
DRG International, Inc. |
Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
|
US7411048B2
(en)
|
2002-11-19 |
2008-08-12 |
Drg International, Inc. |
Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
|
US8017737B2
(en)
*
|
2002-11-19 |
2011-09-13 |
Hasan Kulaksiz |
Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
|
US20040208869A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Uses of anti-integrin alphanubeta3 antibody formulations
|
CA2514653A1
(en)
*
|
2003-01-30 |
2004-08-12 |
Medimmune, Inc. |
Uses of integrin alphavbeta3 antagonists
|
KR20050099536A
(ko)
|
2003-02-06 |
2005-10-13 |
트리펩 아베 |
글리코실화된 특이성 교환체
|
US7335359B2
(en)
*
|
2003-02-06 |
2008-02-26 |
Tripep Ab |
Glycosylated specificity exchangers
|
EP2316487B1
(en)
*
|
2003-04-11 |
2014-06-11 |
MedImmune, LLC |
Recombinant IL-9 antibodies & uses thereof
|
CA2520518A1
(en)
*
|
2003-04-18 |
2004-10-28 |
The University Of British Columbia |
Method for treatment of angiogenic disorders
|
AU2004265226A1
(en)
*
|
2003-05-16 |
2005-02-24 |
Receptor Biologix, Inc. |
Intron fusion proteins, and methods of identifying and using same
|
US7605235B2
(en)
|
2003-05-30 |
2009-10-20 |
Centocor, Inc. |
Anti-tissue factor antibodies and compositions
|
JP2006526641A
(ja)
*
|
2003-05-30 |
2006-11-24 |
セントカー・インコーポレーテツド |
抗−組織因子抗体を用いる腫瘍成長を抑制する方法
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
WO2004113361A2
(en)
*
|
2003-06-20 |
2004-12-29 |
The Regents Of The University Of California |
Novel prokineticin receptor isoforms and methods of use
|
WO2005053683A1
(en)
*
|
2003-11-26 |
2005-06-16 |
Duke University |
A method of preventing or treating glaucoma
|
KR20170102377A
(ko)
|
2004-01-22 |
2017-09-08 |
유니버시티 오브 마이애미 |
국소용 코-엔자임 큐10 제형 및 그의 사용 방법
|
US7271245B2
(en)
*
|
2004-02-13 |
2007-09-18 |
The Scripps Research Institute |
Methods and compositions for inhibition of metastasis
|
WO2005079508A2
(en)
*
|
2004-02-17 |
2005-09-01 |
Cancervax Corporation |
Method and composition for angiogenesis inhibition
|
US7351739B2
(en)
*
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
US8187595B2
(en)
*
|
2004-05-07 |
2012-05-29 |
The University Of North Carolina At Chapel Hill |
Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
|
WO2005117936A2
(en)
*
|
2004-05-07 |
2005-12-15 |
The University Of North Carolina At Chapel Hill |
Method for enhancing or inhibiting insulin-like growth factor-i
|
AU2005245896A1
(en)
*
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
ES2439390T3
(es)
|
2004-06-04 |
2014-01-22 |
The Scripps Research Institute |
Composiciones y procedimiento para el tratamiento de enfermedades neovasculares
|
WO2006012415A2
(en)
*
|
2004-07-20 |
2006-02-02 |
Critical Therapeutics, Inc. |
Rage protein derivatives
|
US20060029544A1
(en)
*
|
2004-08-06 |
2006-02-09 |
The Regents Of The University Of California Office Of Technology Transfer |
Receptor-binding cyclic peptides and methods of use
|
AU2005277641A1
(en)
*
|
2004-08-16 |
2006-03-02 |
Medimmune, Llc |
Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
|
WO2006047639A2
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
KR100679100B1
(ko)
*
|
2004-10-29 |
2007-02-06 |
엘지.필립스 엘시디 주식회사 |
수평 전계 인가형 액정 표시 패널 및 그 제조방법
|
KR20070102684A
(ko)
*
|
2004-12-23 |
2007-10-19 |
몰메드 에스피에이 |
접합 생성물
|
WO2006111925A2
(en)
*
|
2005-04-18 |
2006-10-26 |
Sloan-Kettering Institute For Cancer Research |
Inhibition of tumorigenesis by inhibition of a6b4 integrin
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
US20060286148A1
(en)
*
|
2005-05-18 |
2006-12-21 |
Ppd, Inc. |
Method of forming implants
|
EP2364998A1
(en)
|
2005-06-16 |
2011-09-14 |
The Feinstein Institute for Medical Research |
Antibodies against HMGB1 and fragments thereof
|
EP1893647A2
(en)
|
2005-06-23 |
2008-03-05 |
MedImmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
CA2619654A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Cell Matrix |
Combination therapies for inhibiting integrin-extracellular matrix interactions
|
WO2007084670A2
(en)
|
2006-01-18 |
2007-07-26 |
Merck Patent Gmbh |
Specific therapy using integrin ligands for treating cancer
|
EP1984391A4
(en)
|
2006-01-19 |
2009-08-12 |
Eyegene Inc |
PEPTIDE-SUBSTANCED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES CONNECTED WITH THE VASCULAR SYSTEM
|
AU2007257683A1
(en)
*
|
2006-06-12 |
2007-12-21 |
Symphogen A/S |
Pan-cell surface receptor- specific therapeutics
|
AU2007272970C1
(en)
|
2006-07-11 |
2013-01-10 |
Roy C. Levitt |
Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
|
CA2660519A1
(en)
|
2006-08-10 |
2008-02-21 |
Roy C. Levitt |
Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
|
WO2008045252A2
(en)
|
2006-10-04 |
2008-04-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Engineered integrin binding peptides
|
EA017864B1
(ru)
|
2007-01-18 |
2013-03-29 |
Мерк Патент Гмбх |
Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
|
EP2025685B1
(en)
*
|
2007-08-15 |
2013-06-19 |
Canadian Blood Services |
Monoclonal antibodies against BETA3 integrins
|
WO2009052184A2
(en)
*
|
2007-10-16 |
2009-04-23 |
Receptor Biologix, Inc. |
Compositions comprising optimized her1 and her3 multimers and methods of use thereof
|
WO2009060198A1
(en)
|
2007-11-09 |
2009-05-14 |
Peregrine Pharmaceuticals, Inc. |
Anti-vegf antibody compositions and methods
|
WO2009137807A2
(en)
|
2008-05-08 |
2009-11-12 |
Asuragen, Inc. |
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
EP2323679A4
(en)
|
2008-07-25 |
2012-08-22 |
Univ Colorado |
CLIP HEMMER AND METHOD FOR MODULATING THE IMMUNE FUNCTION
|
DK2352817T3
(en)
|
2008-10-31 |
2016-04-18 |
Univ Louisville Res Found |
OLFACTORY EPITAL DERIVATIVE STEM CELLS AND PROCEDURES FOR USE THEREOF
|
JP2012513589A
(ja)
|
2008-12-23 |
2012-06-14 |
ジーイー・ヘルスケア・リミテッド |
骨髄イメージング剤としての99mTc−ペプチド系化合物の応用
|
JP2012517447A
(ja)
|
2009-02-10 |
2012-08-02 |
ザ スクリプス リサーチ インスティチュート |
化学的にプログラムされたワクチン接種法
|
JP2012528079A
(ja)
|
2009-05-25 |
2012-11-12 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌を治療するためのインテグリンリガンドの連続投与
|
FR2949782B1
(fr)
*
|
2009-09-04 |
2015-10-16 |
Isp Investments Inc |
Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
|
US8778888B2
(en)
*
|
2009-11-06 |
2014-07-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
|
AU2011278700A1
(en)
|
2010-07-16 |
2013-02-28 |
Merck Patent Gmbh |
Peptide for use in the treatment of breast cancer and/or bone metastases
|
MX352025B
(es)
|
2011-02-11 |
2017-11-07 |
Merck Patent Gmbh |
Anticuerpo anti-integrina alfa v para el tratamiento de cancer de prostata.
|
US8722044B2
(en)
|
2011-03-15 |
2014-05-13 |
Janssen Biotech, Inc. |
Human tissue factor antibody and uses thereof
|
RU2531502C2
(ru)
*
|
2011-08-09 |
2014-10-20 |
Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) |
Способ повышения ангиогенной активности стромальных клеток жировой ткани
|
RU2481115C1
(ru)
*
|
2011-10-13 |
2013-05-10 |
Общество с ограниченной ответственностью Научно-Производственное Объединение "Тюменькриобанк" |
Средство для заживления ран "целльгель", способ его получения и способ лечения ран различной этиологии полученным средством
|
US9775803B2
(en)
|
2011-10-19 |
2017-10-03 |
Samsung Electronics Co., Ltd. |
Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
TWI580692B
(zh)
*
|
2012-06-07 |
2017-05-01 |
國立成功大學 |
經修飾纖維黏連蛋白片段或變體及其用途
|
BR112015004119A2
(pt)
|
2012-08-31 |
2017-08-08 |
Univ North Carolina Chapel Hill |
anticorpos monoclonais para melhorar ou inibir o fator de crescimento semelhante à insulina tipo 1 (igf-1)
|
US9587001B2
(en)
|
2012-10-19 |
2017-03-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Conjugated knottin mini-proteins containing non-natural amino acids
|
WO2014087429A1
(en)
|
2012-12-07 |
2014-06-12 |
Council Of Scientific & Industrial Research |
Histidinylated cationic amphiphiles, process for preparation thereof and their liposomal formulation
|
CN105358708A
(zh)
|
2013-03-14 |
2016-02-24 |
儿童医学中心公司 |
Cd36鉴定癌症对象以用于治疗的用途
|
US20190144547A1
(en)
|
2015-11-23 |
2019-05-16 |
Merck Patent Gmbh |
Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
|
US10786471B2
(en)
|
2017-02-06 |
2020-09-29 |
Massachusetts Institute Of Technology |
Methods and products related to glutaminase inhibitors
|
MX2019011717A
(es)
|
2017-03-31 |
2019-12-16 |
Univ California |
Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos.
|
KR102171433B1
(ko)
*
|
2018-05-25 |
2020-11-02 |
고려대학교 산학협력단 |
조직 재생을 위한 Substance P 펩타이드가 고정된 피브린 젤 및 이의 제조방법
|
US20220133913A1
(en)
*
|
2019-07-24 |
2022-05-05 |
Korea Basic Science Institute |
SINGLE DOMAIN ANTIBODY TARGETING aVB3 INTEGRIN
|
BR112022001273A2
(pt)
*
|
2019-08-02 |
2022-06-07 |
Univ California |
Composições e métodos para direcionar e matar células tronco cancerosas (cscs) positivas para alfa-v beta-3 (avss3) (cscs) e tratar cânceres metastáticos e resistentes a fármacos
|
KR20230078657A
(ko)
|
2020-08-27 |
2023-06-02 |
에노시 테라퓨틱스 코퍼레이션 |
자가면역 질환 및 암을 치료하기 위한 방법 및 조성물
|